Number of the records: 1
Minimal residual disease as the target for immunotherapy and gene therapy of cancer (Review)
- 1.
SYSNO ASEP 0024510 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Ostatní články Title Minimal residual disease as the target for immunotherapy and gene therapy of cancer (Review) Title Minimální zbytková choroba jako cíl pro imunoterapii a genovou terapii nádorů (Přehled) Author(s) Bubeník, Jan (UMG-J)
Šímová, Jana (UMG-J) RIDSource Title Oncology Reports - ISSN 1021-335X
Roč. 14, č. 5 (2005), s. 1377-1380Number of pages 4 s. Language eng - English Country GR - Greece Keywords residual tumour disease ; gene therapy ; cytokines Subject RIV EC - Immunology R&D Projects NR7807 GA MZd - Ministry of Health (MZ) NR8004 GA MZd - Ministry of Health (MZ) GA301/04/0492 GA ČR - Czech Science Foundation (CSF) CEZ AV0Z50520514 - UMG-J (2005-2011) Annotation Local recurrences at the site of tumour resection as well as distant micrometastases manifested after surgery represent major problems in oncology. Adjuvant immunotherapy and gene therapy may help to cope, at least partially, with these problems. Adjuvant modalities may be more effective in treating residual tumour disease compared to bulky tumours, owing to a favourable effector/target cell ratio. The purpose of this review was to summarize, evaluate and discuss the results obtained with adjuvant immunotherapy and immunomodulatory gene therapy of surgical minimal residual tumour disease in experimental and clinical tumour systems. The prospects and limitations of adjuvant therapeutic modalities will be considered. Workplace Institute of Molecular Genetics Contact Nikol Škňouřilová, nikol.sknourilova@img.cas.cz, Tel.: 241 063 217 Year of Publishing 2006
Number of the records: 1